Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Top Cited Papers
- 6 July 2017
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 377 (1) , 62-70
- https://doi.org/10.1056/nejmra1510062
Abstract
High-quality evidence is what we use to guide medical practice. The standard approach to generating this evidence — a series of clinical trials, each investigating one or two interventions in a single disease — has become ever more expensive and challenging to execute. As a result, important clinical questions go unanswered. The conduct of “precision medicine” trials to evaluate targeted therapies creates challenges in recruiting patients with rare genetic subtypes of a disease. There is also increasing interest in performing mechanism-based trials in which eligibility is based on criteria other than traditional disease definitions. The common denominator is a need to answer more questions more efficiently and in less time.Keywords
This publication has 29 references indexed in Scilit:
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsNew England Journal of Medicine, 2015
- The Platform TrialJAMA, 2015
- Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic MedicineJournal of Clinical Oncology, 2015
- The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical researchMolecular Oncology, 2015
- Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityMolecular Oncology, 2014
- Considerations for the successful co-development of targeted cancer therapies and companion diagnosticsNature Reviews Drug Discovery, 2013
- Accelerating Identification and Regulatory Approval of Investigational Cancer DrugsJAMA, 2011
- The BATTLE Trial: Personalizing Therapy for Lung CancerCancer Discovery, 2011
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant ChemotherapyClinical Pharmacology & Therapeutics, 2009
- Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine KinasesClinical Cancer Research, 2008